The Burrill Report

The Burrill Report (November 11, 2013): Cytori Attracts Strategic Investment from Asia Partner (.MP3,17.08 Mb)

Cytori Therapeutics this month announced an agreement worth up to $531 million with Lorem Vascular to commercialize Cytori’s cell therapy for the cardiovascular, renal, and diabetes markets in China and elsewhere. The agreement includes a $24 million equity investment, as well as orders, and milestones for as much as $500 million. We spoke to Chris Calhoun, CEO of Cytori, about the deal, what it means for the company, and what’s compelling about its regenerative cell therapy.

November 07, 2013
http://www.burrillreport.com/article-cytori_attracts_strategic_investment_from_asia_partner_.html